Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
AstraZeneca is pushing for a new treatment option in advanced lung cancer. The Anglo-Swedish drugmaker has filed an FDA application for the ORPATHYS-TAGRISSO combination, co-developed with HUTCHMED (China). If approved, the combo could expand the treatment toolkit for patients battling advanced lung cancer.
AstraZeneca has taken a significant step toward expanding lung cancer treatment options by filing an application with the US Food and Drug Administration (FDA) for the ORPATHYS-TAGRISSO drug combination in patients with advanced lung cancer.
ORPATHYS is jointly developed by AstraZeneca and Hong Kong-listed HUTCHMED (China), with AstraZeneca handling commercialization. TAGRISSO (osimertinib) is already a well-established targeted therapy for certain lung cancers, and pairing it with ORPATHYS could potentially offer a more potent treatment approach for patients with advanced disease.
Key Takeaways:
Why it matters: Advanced lung cancer remains one of the leading causes of cancer-related deaths worldwide, and new combination therapies could offer patients more effective options. FDA approval of this combo would mark a meaningful addition to the oncology arsenal, potentially improving outcomes for a patient population with limited alternatives.
